Floatz logo

Tezacaftor

Cystic Fibrosis

Vertex Pharmaceuticals IncorporatedSmall moleculePhase 4 / ApprovedActive
A
80/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
84/ 100
Competitive Position
73/ 100

Competitive context

81 Active assets in the Cystic Fibrosis cohort.

Asset / SponsorPhaseRating
Liprotamase
Anthera Pharmaceuticals
Phase 4BBB
Lumacaftor
Hospices Civils de Lyon
Phase 4BBB
Ivacaftor
Meyer Children's Hospital IRCCS
Phase 4BBB
ELEXACAFTOR
Meyer Children's Hospital IRCCS
Phase 4BBB
vx-121
Vertex Pharmaceuticals Incorporated
Phase 3BBB

View all 50 →

Same molecule, other indications

Tezacaftor is also rated in:

Non-cystic Fibrosis BronchiectasisDormant
BB
Indicative ·
65 / 100
View asset →
Muscle LossDormant
D
Indicative ·
30 / 100
View asset →
Bone LossDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →